Drugmakers are racing the clock—and the clock is patent expiry.
When a blockbuster’s exclusivity window closes, the market doesn’t just “open.” It reorders. Prices compress, formularies tighten, and competitors move from “maybe” to “inevitable.” In t…

Two clocks. One drug. And a deadline that can’t be negotiated.
In pharma, timing isn’t just strategy—it’s survival.
A lot of teams talk about “patent life” as if it’s the only clock that matters. But in practice, your drug’s competitive runway is often…

Small molecules vs. biologics: the patent playbook changes—and so should your LOE strategy
The market doesn’t care whether your R&D team thinks in “mechanisms.” Investors, competitors, and regulators think in exclusivity timelines—and the exclusivi…

Biopharma’s next growth cycle won’t be won in the lab—it’ll be won in the tender room.
If you sell to European healthcare systems, you already know the uncomfortable truth: when a drug hits loss of exclusivity, the market doesn’t “slow down.” It gets r…

Pharma doesn’t always need a new molecule to make billions. Sometimes it just needs a new label.
Here’s the uncomfortable truth behind modern drug economics: a “new drug” can be nothing more than an old molecule with a fresh indication, a tighter formu…